HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.0%

Neg 0% Neu 88% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $9 price target.